Catalyst Biosciences Announces Poster Presentation at the Association for Research in Vision and Ophthalmology Annual Meeting...
March 06 2019 - 8:00AM
Catalyst Biosciences, Inc. (NASDAQ: CBIO), a clinical-stage
biopharmaceutical company focused on developing novel medicines to
address hematology indications, today announced the presentation of
a poster, in collaboration with partner Mosaic Biosciences, at the
2019 Annual Meeting of the Association for Research in Vision and
Ophthalmology (ARVO), being held in Vancouver, British Columbia,
from April 28-May 2, 2019. The data will focus on preclinical
pharmacokinetic data of pegylated CB 2782, Catalyst’s preclinical
anti-complement candidate for the treatment of dry age-related
macular degeneration (dry AMD).
Poster presentation details
|
|
|
|
|
|
|
|
Presentation Title: |
|
Pegylated CB 2782: a Complement Factor
C3-Inactivating Protease and Potential Long-Acting Treatment for
Dry AMD |
|
|
|
|
|
|
|
|
|
|
|
Presenter: |
|
Eric Furfine, Ph.D. |
|
|
|
|
|
|
|
|
|
|
|
Session: |
|
AMD therapies (excluding anti-VEGF) |
|
|
|
|
|
|
|
|
|
|
|
Date/Time: |
|
Sunday, April 28, 2019 from 1:00 - 2:45 p.m.
PDT |
|
|
|
A copy of the presentation materials can be
accessed on the Events and Presentations section of the Catalyst
website once the presentation concludes.
About Catalyst BiosciencesCatalyst is a
clinical-stage biopharmaceutical company developing novel medicines
to address hematology indications. Catalyst is focused on the field
of hemostasis, including the subcutaneous prophylaxis of hemophilia
and facilitating surgery in individuals with hemophilia. For more
information, please visit www.catalystbiosciences.com.
Forward-Looking StatementsThis press release
contains forward-looking statements that involve substantial risks
and uncertainties. All statements, other than statement of
historical facts (including, but not limited to, statements that
contain words such as “will,” “believes,” “plans,” “anticipates,”
“expects,” “estimates”) are forward-looking statements. Actual
results or events could differ materially from the plans,
intentions, expectations and projections disclosed in the
forward-looking statements. Various important factors could cause
actual results or events to differ materially from the
forward-looking statements that the Company makes, including, but
not limited to, the risk that trials and studies may be delayed and
may not have satisfactory outcomes, that human trials will not
replicate the results from animal studies, that potential adverse
effects may arise from the testing or use of the Company’s
products, including the generation of antibodies, the risk that
costs required to develop or manufacture the Company’s products
will be higher than anticipated, competition and other factors that
affect our ability to establish collaborations on commercially
reasonable terms and other risks described in the “Risk Factors”
section of the Company’s Quarterly Report on Form 10-Q for the
quarter ended September 30, 2018 filed with the Securities and
Exchange Commission on November 1, 2018, and with other filings
with the Securities and Exchange Commission. The Company does not
assume any obligation to update any forward-looking statements,
except as required by law.
Contacts:Investors:Fletcher
Payne, CFOCatalyst Biosciences,
Inc.1.650.871.0761investors@catbio.com
Media:Josephine Belluardo, Ph.D.LifeSci Public
Relations1.646.751.4361jo@lifescipublicrelations.com
Catalyst Biosciences (NASDAQ:CBIO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Catalyst Biosciences (NASDAQ:CBIO)
Historical Stock Chart
From Sep 2023 to Sep 2024